EMMANUEL FANTONE: Open Payments
NPI 1871632547 · WOODLAND HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,003 in 167 payments from 11 companies in 2025. Trend: 2023 $2,982 · 2024 $1,596 · 2025 $4,003
Food & beverage: $3,753Education: $250
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 43 | $725 |
| E.R. Squibb & Sons, L.L.C. | 16 | $712 |
| Teva Pharmaceuticals USA, Inc. | 14 | $576 |
| Alkermes, Inc. | 21 | $509 |
| Vanda Pharmaceuticals Inc. | 22 | $355 |
| Otsuka America Pharmaceutical, Inc. | 13 | $286 |
| ABBVIE INC. | 10 | $224 |
| Janssen Pharmaceuticals, Inc | 9 | $215 |
| Axsome Therapeutics, Inc. | 8 | $150 |
| Neurocrine BioSciences, Inc. | 6 | $138 |
Products named: CAPLYTA, COBENFY, ARISTADA, FANAPT, UZEDY, VRAYLAR, INVEGA SUSTENNA, REXULTI.
Industry payments across CA — which companies pay providers there.
